Systemic or local deficiencies of Folates or other micronutrients have a substantial impact on the course of an illness and often provide reason for a specific chronic disease.

Correcting such deficiencies with the «best possible form of Folate» is an affordable, safe way to delay or halt the progression of degenerative, harmful sickness. Some studies have shown improvements in the condition.

Aprofol facilitates the collaboration of various disciplines and applies documented facts on the properties of the different folate forms with recent scientific findings. Close collaborations with key opinion leaders in the Folate-field, in ophthalmology, autism and skin disorders are in place. Regulatoy experts support us in gaining approval with health autorities. Collaborations with carefully selected contract development and manufacturing organizations allow an efficient and fast route to the people who are in urgent need for safe, affordable treatments.

Keynote Martin Ulmann, CEO and Founder of Aprofol AG